PHK
TEVA icon

Point72 Hong Kong’s Teva Pharmaceuticals TEVA Stock Holding History

Point72 Hong Kong’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,162
Closed -$83.9K – 639
2024
Q2 		$83.9K Buy
+5,162
New +$79.5K 0.01% 344

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Point72 Hong Kong's TEVA Position: Q3 2024 in Review

Point72 Hong Kong sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 5,162 shares — an estimated $83.9K sold.

Point72 Hong Kong first reported a position in TEVA in Q2 2024 and held it in 1 quarter. The position peaked at $83.9K in Q2 2024. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Point72 Hong Kong reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Point72 Hong Kong sold 5,162 Teva Pharmaceuticals shares in Q3 2024, an estimated $83.9K.
  • Point72 Hong Kong first reported a position in Teva Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Point72 Hong Kong's Teva Pharmaceuticals position peaked at $83.9K in Q2 2024.
  • 542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Point72 Hong Kong's 13F filing for Q3 2024, filed 14 Nov 2024.